Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
A synthetic small molecule belonging to the phenylpyrimidine class of organic compounds. It features a pyrazolo[1,5-a]pyrimidine core substituted with a 2,3-dichlorophenyl group and a pyridin-4-ylmethyl amine moiety. The compound is catalogued as an experimental molecule and has been structurally characterized in complex with cyclin-dependent kinase 2 (CDK2), suggesting its use as a kinase inhibitor in biochemical research. There are no approved therapeutic indications or clinical trial data available for this compound as of now. Its mechanism of action is presumed to involve inhibition of protein kinases such as CDK2 based on structural studies.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 5-(2,3-dichlorophenyl)-N-(pyridin-4-ylmethyl)pyrazolo[1,5-a]pyrimidin-7-amine.